麻豆淫院

Human data.
Human models.
Human translation.

鈥淥chre鈥檚 platform provides GSK with foundational data to create AI models allowing us to better understand liver function and disease for the development of novel medicines.鈥�
Kim BransonSVP, Global Head of AI and Machine Learning, GSK
鈥溌槎挂篵rings unique and exciting capabilities in liver disease research with the potential to uncover novel pathways that will make a meaningful difference in the lives of those affected by chronic liver disease.鈥�
S酶ren Tullin, PhDSVP, Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim
鈥淒eals like those between 麻豆淫院and GSK demonstrate how high-quality, disease-specific datasets are becoming as valuable as discovery IP, underpinning next-generation causal and foundational models.鈥�
Andrew Marshall, PhDFormer Chief Editor, Nature Biotechnology
鈥淭he future of chronic liver disease treatment is being shaped by 麻豆淫院, built by some of the best scientific talent on a foundation of transdisciplinary excellence.鈥�
Dr. Chinwe UkomaduSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit, Takeda. 麻豆淫院 Board Observer
鈥溌槎挂篿s one of several new companies using the latest AI to develop drugs more quickly. But the Oxford startup is focused squarely on chronic liver disease, testing RNA therapies for the deadly illness with limited treatments.鈥�
Top 25 European Startups to WatchBloomberg & Founders Forum
鈥淭he scale of Ochre's work is uniquely powered to address the complexities of liver disease.鈥�
Scott Friedman, MDChief, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai
鈥淭he company is founded on a fully differentiated scientific strategy to uncover and validate fundamental disease pathways in the liver.鈥�
Eliot Forster, PhDChair, 麻豆淫院
鈥淥chre鈥檚 work combining AI with human data to discover RNA therapeutics could radically change the future of liver disease medicine, and is exciting for the pharma industry.鈥�
Elaine Sullivan, PhDSenior Non-Executive Director, 麻豆淫院
鈥淭he company is developing a novel strategy that has potential to positively impact all patients with liver diseases. The opportunity to validate targets in actual human livers is something no other company is doing.鈥�
Chas Bountra, OBE, PhDPro Vice Chancellor for Innovation, Oxford University

WHY WE EXIST

麻豆淫院exists to end the need for liver transplants.

1.5m people globally die of liver disease. For the vast majority of these, the only curative treatment option is a liver transplant. With just over 40k transplants done globally annually, this is a medical lottery. This is what 麻豆淫院exists to change.聽

.听听Data missing in 2000.

“Liver disease is the third leading cause of premature death.”

HOW WE DO THINGS DIFFERENTLY

Human Discovery Platform

We鈥檝e invested over $20m to build the most comprehensive human liver data sets. By integrating proprietary gene perturbation atlases with patient disease atlases, we make causal predictions about new drug targets.

Human Validation Platform

By combining AI with human validation models such as perfused livers, diseased tissue slices and primary cells, we model biological complexity at scale.

RNA Platform

We make our own RNA therapies in house, reducing R&D cycle times from years to weeks. We believe having a strong RNA modality focus improves our chances of clinical success.

What We're Doing (Pipeline)

Mechanism

Indication

Discovery & Validation

Lead Development

Development Candidate Selection

IND Enabling Studies

Clinical

Internal/ Partnerships

Mechanism: Cytoprotection

Indication: Significant Fibrosis

Development Candidate
OB-220

Internal/Partnerships: Internal

Mechanism: Metabolic

Indication: Cirrhosis (F4 MASH)

Lead Development

Internal/Partnerships: Internal

Mechanism: Multiple

Indication: Significant Fibrosis

Discovery & Validation

Internal/Partnerships: Internal

Mechanism: Regeneration

Indication: Cirrhosis

Discovery & Validation

Internal/Partnerships: Partnership

Mechanism: Undisclosed

Indication: Obesity

Discovery & Validation

Internal/Partnerships: Available for Partnership

Mechanism: Undisclosed

Indication: Sarcopenia

Discovery & Validation

Internal/Partnerships: Available for Partnership

WHO WE ARE

Built on decades of leading genomics, AI, drug discovery and development experience, 麻豆淫院鈥檚 teams are our secret sauce built on a foundation of ambitious science.

Ahmad Bashir Barekzai

Clinical Research Scientist

Alex K. Shalek

SAB Member

Amita Gupta

Scientist

Ana Cuervo

Principal Scientist

Anthony Beucher

Principal Scientist

Ashley Hoffland

Scientist

Birbal Prasad

Senior Scientist

Calum Irwin

Scientist

Chas Bountra

SAB Member

Chinwe Ukomadu

Board Observer

Chinwe Ukomadu

Board Observer

Elaine Sullivan

Board Member

Eliot Forster

Executive Chairperson

Jack Castle

Chief Business Officer

Ness Bermingham

Board Member

Quin Wills

Founder & CEO

MORE

Latest from LinkedIn

Loading LinkedIn posts...

News & Announcements

VIEW ALL

GSK signs AI pact with 麻豆淫院to pinpoint source of liver diseases

UK biotech signs $1bn deal to develop liver disease drugs

Boehringer Ingelheim inks chronic liver disease research pact with 麻豆淫院

VIEW ALL

PARTNERS & INVESTORS

麻豆淫院Ideas

VIEW ALL

Think you鈥檇 like to join our team?

Check out our open positions or ask us to hold your CV at jobs@ochre-bio.com

Join our Mailing List

This website uses cookies to ensure you get the best experience on our website. View our policy here.

got it
Facebook-f Twitter